Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2015 1
2016 4
2017 11
2018 52
2019 73
2020 94
2021 124
2022 124
2023 111
2024 59

Text availability

Article attribute

Article type

Publication date

Search Results

588 results

Results by year

Filters applied: . Clear all
Page 1
Erenumab.
[No authors listed] [No authors listed] 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Nov 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000991 Free Books & Documents. Review.
No information is available on the passage of erenumab into breastmilk. Because erenumab is a large protein molecule with a molecular weight of 150,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's ga …
No information is available on the passage of erenumab into breastmilk. Because erenumab is a large protein molecule with a mo …
Erenumab.
[No authors listed] [No authors listed] 2018 Aug 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2018 Aug 8. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643409 Free Books & Documents. Review.
Erenumab is a monoclonal antibody to the receptor for calcitonin gene related peptide which plays a role in inducing migraine headaches. Erenumab is used for prevention of migraine in patients with episodic or chronic migraine headaches. ...
Erenumab is a monoclonal antibody to the receptor for calcitonin gene related peptide which plays a role in inducing migraine headach …
Erenumab for episodic migraine.
Datta A, Gupta S, Maryala S, Aggarwal V, Chopra P, Jain S. Datta A, et al. Pain Manag. 2022 Jul;12(5):587-594. doi: 10.2217/pmt-2021-0077. Epub 2022 Mar 22. Pain Manag. 2022. PMID: 35313740 Review.
Erenumab faces significant limitations because of its high financial cost. ...However, because of its high cost, patients still face significant barriers to access to erenumab. Additional long-term real-world data are needed to understand the current role of eren …
Erenumab faces significant limitations because of its high financial cost. ...However, because of its high cost, patients still face …
Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial.
Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S, Hours-Zesiger P, Nickisch J, Sieder C, Hentschke C, Maier-Peuschel M. Reuter U, et al. Cephalalgia. 2022 Feb;42(2):108-118. doi: 10.1177/03331024211053571. Epub 2021 Nov 7. Cephalalgia. 2022. PMID: 34743579 Free PMC article. Clinical Trial.
BACKGROUND: We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related peptide receptor, to topiramate for migraine prophylaxis in adults. ...Patients with 4 migraine days per month and naive to study drugs were rand …
BACKGROUND: We compared the tolerability and efficacy of erenumab, a monoclonal antibody binding to the calcitonin gene-related pepti …
A Controlled Trial of Erenumab for Episodic Migraine.
Goadsby PJ, Reuter U, Hallström Y, Broessner G, Bonner JH, Zhang F, Sapra S, Picard H, Mikol DD, Lenz RA. Goadsby PJ, et al. N Engl J Med. 2017 Nov 30;377(22):2123-2132. doi: 10.1056/NEJMoa1705848. N Engl J Med. 2017. PMID: 29171821 Free article. Clinical Trial.
RESULTS: A total of 955 patients underwent randomization: 317 were assigned to the 70-mg erenumab group, 319 to the 140-mg erenumab group, and 319 to the placebo group. ...A 50% or greater reduction in the mean number of migraine days per month was achieved for 43.3 …
RESULTS: A total of 955 patients underwent randomization: 317 were assigned to the 70-mg erenumab group, 319 to the 140-mg erenuma …
Erenumab in the treatment of migraine.
Jain S, Yuan H, Spare N, Silberstein SD. Jain S, et al. Pain Manag. 2018 Nov 1;8(6):415-426. doi: 10.2217/pmt-2018-0037. Epub 2018 Sep 21. Pain Manag. 2018. PMID: 30235976 Review.
This review will focus on the first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine: erenumab. Two Phase II trials (one for episodic migraine and one for chronic migraine) and two Phase III trials for episodic migraine have been p …
This review will focus on the first US FDA-approved CGRP-receptor monoclonal antibody developed for the prevention of migraine: erenumab …
Erenumab for episodic migraine prophylaxis.
Overeem LH, Neeb L, Reuter U. Overeem LH, et al. Expert Rev Neurother. 2019 Aug;19(8):751-757. doi: 10.1080/14737175.2019.1565996. Epub 2019 Jan 29. Expert Rev Neurother. 2019. PMID: 30614741 Review.
Introduction: This paper reviews placebo-controlled randomized double-blind studies with erenumab for the prevention of migraine. Erenumab is a fully human monoclonal antibody (mAb), which specifically blocks the calcitonin gene-related peptide (GGRP) receptor. ...T …
Introduction: This paper reviews placebo-controlled randomized double-blind studies with erenumab for the prevention of migraine. …
Erenumab-aooe.
Stoker K, Baker DE. Stoker K, et al. Hosp Pharm. 2018 Dec;53(6):363-368. doi: 10.1177/0018578718797295. Epub 2018 Sep 1. Hosp Pharm. 2018. PMID: 30559520 Free PMC article. Review.
Erenumab: First Global Approval.
Markham A. Markham A. Drugs. 2018 Jul;78(11):1157-1161. doi: 10.1007/s40265-018-0944-0. Drugs. 2018. PMID: 29968151 Review.
Amgen and Novartis are developing erenumab (AIMOVIG, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related peptide (CGRP) receptor antagonist-for the prevention of migraine. ...This article summarizes the milestones in the development of erenum …
Amgen and Novartis are developing erenumab (AIMOVIG, erenumab-aooe)-a fully human monoclonal antibody calcitonin gene-related …
Erenumab efficacy in migraine headache prophylaxis: A systematic review.
Bagherzadeh-Fard M, Amin Yazdanifar M, Sadeghalvad M, Rezaei N. Bagherzadeh-Fard M, et al. Int Immunopharmacol. 2023 Apr;117:109366. doi: 10.1016/j.intimp.2022.109366. Epub 2023 Mar 9. Int Immunopharmacol. 2023. PMID: 37012858 Review.
The efficacy of Erenumab was initiated in the first week of administration and sustained throughout and after treatment. ...Erenumab also had favorable outcomes in combination therapy with other preventive drugs like Onabotulinumtoxin-A. ...
The efficacy of Erenumab was initiated in the first week of administration and sustained throughout and after treatment. ...Erenum …
588 results